[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-001", "question": "A 14-year-old competitive swimmer with genotype-positive, phenotype-negative catecholaminergic polymorphic ventricular tachycardia (RYR2 exon 3 p.Arg2474Ser mutation) experiences syncope during a sanctioned meet. Ambulatory monitoring shows bidirectional ventricular tachycardia at 180 bpm during exercise. Baseline QTc is 410 ms. Which long-term pharmacologic strategy is most likely to prevent arrhythmic recurrence?", "options": ["Nadolol 1 mg/kg/day with exercise restriction", "Flecainide 100 mg twice daily as monotherapy", "Nadolol 1 mg/kg/day plus flecainide 100 mg twice daily", "Verapamil 240 mg daily with ICD backup", "ICD implantation with sotalol 120 mg twice daily"], "answer": "C", "answer_index": 2, "explanation": "Specific RYR2 mutations in the channel core (exon 3) demonstrate poor response to beta-blockade alone; combination therapy with flecainide provides synergistic RyR2 stabilization by reducing calcium leak. Verapamil lacks efficacy in CPVT, and ICD shocks can trigger catecholamine surge and arrhythmic storms.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C (primary; secondary U leading to M). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: 14-year-old with RYR2 exon 3 p.Arg2474Ser mutation (genotype-positive, phenotype-negative CPVT), syncope during swimming, bidirectional VT at 180 bpm on exercise monitoring, normal QTc 410 ms; question seeks optimal long-term pharmacologic strategy to prevent recurrence. Main logical issue(s): Internal contradiction in stem—the specified mutation p.Arg2474Ser cannot be in exon 3, as exon 3 encodes early N-terminal residues (around 1-150), while position 2474 is in exon 47 (central domain); this incoherence makes the item's genetic premise unsolvable and underspecifies whether standard CPVT management or mutation-specific logic applies, allowing multiple defensible options (e.g., A as initial beta-blocker per guidelines, C if assuming poor BB response). Main medical accuracy issue(s): Inaccurate genetics—exon 3 is not 'channel core' (rationale error); p.R2474S is central domain, not exon 3; CPVT standard (HRS guidelines) starts nadolol post-event, adding flecainide for breakthroughs, not routinely combo upfront for this mutation; verapamil ineffective, ICD risks storms accurate but not primary. Minimal fix: Edit stem to 'RYR2 p.Arg2474Ser mutation (central domain, exon 47)' and update rationale to reflect standard domain-specific data, making C defensible if intended for refractory cases.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (primary; secondary U leading to M). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: 14-year-old with RYR2 exon 3 p.Arg2474Ser mutation (genotype-positive, phenotype-negative CPVT), syncope during swimming, bidirectional VT at 180 bpm on exercise monitoring, normal QTc 410 ms; question seeks optimal long-term pharmacologic strategy to prevent recurrence. Main logical issue(s): Internal contradiction in stem—the specified mutation p.Arg2474Ser cannot be in exon 3, as exon 3 encodes early N-terminal residues (around 1-150), while position 2474 is in exon 47 (central domain); this incoherence makes the item's genetic premise unsolvable and underspecifies whether standard CPVT management or mutation-specific logic applies, allowing multiple defensible options (e.g., A as initial beta-blocker per guidelines, C if assuming poor BB response). Main medical accuracy issue(s): Inaccurate genetics—exon 3 is not 'channel core' (rationale error); p.R2474S is central domain, not exon 3; CPVT standard (HRS guidelines) starts nadolol post-event, adding flecainide for breakthroughs, not routinely combo upfront for this mutation; verapamil ineffective, ICD risks storms accurate but not primary. Minimal fix: Edit stem to 'RYR2 p.Arg2474Ser mutation (central domain, exon 47)' and update rationale to reflect standard domain-specific data, making C defensible if intended for refractory cases.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-002", "question": "A 72-hour-old term neonate presents with lethargy and poor feeding. Plasma ammonia is 920 μmol/L, arterial pH 7.32, anion gap 12 mEq/L. Urine orotic acid is undetectable. Plasma amino acids show elevated glutamine with decreased citrulline and arginine. Which intervention directly addresses the primary enzymatic defect?", "options": ["Intravenous sodium phenylbutyrate 250 mg/kg", "Oral carglumic acid 100 mg/kg", "Emergent hemodialysis", "Intravenous arginine HCl 200 mg/kg", "Protein restriction to 0.5 g/kg/day"], "answer": "B", "answer_index": 1, "explanation": "Carbamoyl phosphate synthetase I deficiency is uniquely responsive to carglumic acid, which allosterically activates the defective enzyme by increasing its affinity for N-acetylglutamate. Sodium phenylbutyrate and arginine require functional CPS1 activity to excrete nitrogen and are ineffective. Hemodialysis is temporizing but not disease-specific.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Neonatal hyperammonemia (920 μmol/L) with lethargy, poor feeding, mild acidosis (pH 7.32, normal anion gap), undetectable urine orotic acid, elevated glutamine, and decreased citrulline/arginine, indicating proximal urea cycle disorder (CPS1 or NAGS deficiency).\\nMain logical issue(s), if any: None; the stem provides sufficient discriminating findings to identify a single best intervention targeting the enzymatic defect without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: The vignette and options align with standard medical knowledge for urea cycle disorders; however, the author rationale inaccurately claims sodium phenylbutyrate and arginine require functional CPS1 and are ineffective—phenylbutyrate actually bypasses the urea cycle by conjugating glutamine for excretion and is standard in CPS1 deficiency. The item implies carglumic acid directly addresses the defect (by activating CPS1), which is accurate for NAGS and some CPS1 cases per guidelines, but misses nuance on variable CPS1 responsiveness.\\nMinimal fix: Add to the stem 'genetic testing confirms NAGS deficiency' to unambiguously specify the defect and enhance precision without altering the keyed answer.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Neonatal hyperammonemia (920 μmol/L) with lethargy, poor feeding, mild acidosis (pH 7.32, normal anion gap), undetectable urine orotic acid, elevated glutamine, and decreased citrulline/arginine, indicating proximal urea cycle disorder (CPS1 or NAGS deficiency).\nMain logical issue(s), if any: None; the stem provides sufficient discriminating findings to identify a single best intervention targeting the enzymatic defect without contradictions or underspecification.\nMain medical accuracy issue(s), if any: The vignette and options align with standard medical knowledge for urea cycle disorders; however, the author rationale inaccurately claims sodium phenylbutyrate and arginine require functional CPS1 and are ineffective—phenylbutyrate actually bypasses the urea cycle by conjugating glutamine for excretion and is standard in CPS1 deficiency. The item implies carglumic acid directly addresses the defect (by activating CPS1), which is accurate for NAGS and some CPS1 cases per guidelines, but misses nuance on variable CPS1 responsiveness.\nMinimal fix: Add to the stem 'genetic testing confirms NAGS deficiency' to unambiguously specify the defect and enhance precision without altering the keyed answer.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-003", "question": "A 30-year-old diver is stung on the neck by a thumbnail-sized jellyfish off the Great Barrier Reef. Initial pain resolves, but 45 minutes later develops severe lower back pain, dyspnea, and pulmonary edema with systolic BP 190 mmHg. Which therapy specifically antagonizes the pathophysiologic cascade?", "options": ["Chironex fleckeri antivenom 20,000 units IV", "Magnesium sulfate 50 mg/kg IV bolus then infusion", "Calcium gluconate 1 g IV", "Fentanyl 100 μg IV", "Verapamil 5 mg IV"], "answer": "B", "answer_index": 1, "explanation": "Irukandji syndrome from Carukia barnesi triggers massive catecholamine release via voltage-gated sodium channel modulation; magnesium sulfate inhibits catecholamine release and reduces calcium influx at presynaptic terminals. Chironex antivenom is ineffective against Irukandji toxins, while calcium may worsen catecholamine release.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include: thumbnail-sized jellyfish sting off Great Barrier Reef (suggestive of Carukia barnesi), delayed onset (45 minutes) of severe lower back pain, dyspnea, pulmonary edema, and hypertension (systolic BP 190 mmHg), pointing to Irukandji syndrome's catecholamine surge without immediate severe symptoms ruling out box jellyfish. These discriminate toward therapy antagonizing the pathophysiologic cascade of massive catecholamine release. Main logical issue(s): None; stem provides sufficient details for unique best answer without contradictions or underspecification, as options are distinct and vignette aligns with classic presentation allowing clear discrimination. Main medical accuracy issue(s): None; consistent with current standards where magnesium sulfate inhibits presynaptic calcium influx and catecholamine release in Irukandji syndrome, while Chironex antivenom is ineffective, calcium may exacerbate, fentanyl addresses pain only, and verapamil is not primary. Item reflects board-relevant knowledge on marine envenomations. Minimal fix: N/A as item is unambiguous and accurate; optionally, add 'delayed symptom onset' explicitly in stem for emphasis, though not necessary.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include: thumbnail-sized jellyfish sting off Great Barrier Reef (suggestive of Carukia barnesi), delayed onset (45 minutes) of severe lower back pain, dyspnea, pulmonary edema, and hypertension (systolic BP 190 mmHg), pointing to Irukandji syndrome's catecholamine surge without immediate severe symptoms ruling out box jellyfish. These discriminate toward therapy antagonizing the pathophysiologic cascade of massive catecholamine release. Main logical issue(s): None; stem provides sufficient details for unique best answer without contradictions or underspecification, as options are distinct and vignette aligns with classic presentation allowing clear discrimination. Main medical accuracy issue(s): None; consistent with current standards where magnesium sulfate inhibits presynaptic calcium influx and catecholamine release in Irukandji syndrome, while Chironex antivenom is ineffective, calcium may exacerbate, fentanyl addresses pain only, and verapamil is not primary. Item reflects board-relevant knowledge on marine envenomations. Minimal fix: N/A as item is unambiguous and accurate; optionally, add 'delayed symptom onset' explicitly in stem for emphasis, though not necessary.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-004", "question": "An 8-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. Biopsy shows necrotizing vasculitis without immune complex deposition. Immunoglobulins show IgM 28 mg/dL (low). Genetic testing reveals ADA2 biallelic loss-of-function mutations. Which biologic therapy directly interrupts the disease-driving signaling cascade?", "options": ["High-dose prednisone 2 mg/kg/day", "Cyclophosphamide 500 mg/m² monthly", "Etanercept 0.4 mg/kg twice weekly", "Adalimumab 20 mg every 2 weeks", "Anakinra 2 mg/kg daily"], "answer": "D", "answer_index": 3, "explanation": "Deficiency of adenosine deaminase 2 causes uncontrolled type I interferon and TNF-α signaling; TNF inhibition with adalimumab (monoclonal antibody) is superior to etanercept (soluble receptor) which can bind mutant ADA2 and paradoxically worsen inflammation. Anakinra targets IL-1 and is ineffective for DADA2.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: M (multiple answers defensible)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues that drive (or fail to drive) a unique best answer: 8-year-old boy with recurrent lacunar strokes, livedo racemosa, systemic vasculitis, necrotizing vasculitis without immune complex deposition, low IgM (28 mg/dL), and confirmed biallelic loss-of-function ADA2 mutations, pointing to DADA2 requiring therapy targeting TNF-α signaling.\\nMain logical issue(s), if any: Stem establishes DADA2 diagnosis, where TNF-α drives pathology, but lacks any discriminating details (e.g., prior treatment failure or specific phenotype) to favor adalimumab (D) over etanercept (C); both are established TNF inhibitors that directly interrupt the cascade, rendering C and D equally defensible as best biologic therapy.\\nMain medical accuracy issue(s), if any: Vignette accurately depicts DADA2 features and genetics; however, author rationale inaccurately claims adalimumab superiority due to etanercept binding mutant ADA2 and paradoxically worsening inflammation, which contradicts mainstream literature—etanercept is commonly used and effective in DADA2 without such effects. Anakinra's stated ineffectiveness aligns with evidence, as DADA2 is not IL-1 driven.\\nMinimal fix: Add to stem: 'with prior worsening of vasculitis on etanercept' to provide a defensible reason for selecting adalimumab, assuming case-specific evidence supports this switch for uniqueness and accuracy.\",\n\"medical_accuracy_score\": 2,\n\"logical_validity\": false,\n\"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues that drive (or fail to drive) a unique best answer: 8-year-old boy with recurrent lacunar strokes, livedo racemosa, systemic vasculitis, necrotizing vasculitis without immune complex deposition, low IgM (28 mg/dL), and confirmed biallelic loss-of-function ADA2 mutations, pointing to DADA2 requiring therapy targeting TNF-α signaling.\nMain logical issue(s), if any: Stem establishes DADA2 diagnosis, where TNF-α drives pathology, but lacks any discriminating details (e.g., prior treatment failure or specific phenotype) to favor adalimumab (D) over etanercept (C); both are established TNF inhibitors that directly interrupt the cascade, rendering C and D equally defensible as best biologic therapy.\nMain medical accuracy issue(s), if any: Vignette accurately depicts DADA2 features and genetics; however, author rationale inaccurately claims adalimumab superiority due to etanercept binding mutant ADA2 and paradoxically worsening inflammation, which contradicts mainstream literature—etanercept is commonly used and effective in DADA2 without such effects. Anakinra's stated ineffectiveness aligns with evidence, as DADA2 is not IL-1 driven.\nMinimal fix: Add to stem: 'with prior worsening of vasculitis on etanercept' to provide a defensible reason for selecting adalimumab, assuming case-specific evidence supports this switch for uniqueness and accuracy.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-005", "question": "A 23-year-old graduate student has persistent fasting glucose 108-115 mg/dL and HbA1c 6.1-6.3% discovered on routine screening. BMI is 22 kg/m², islet autoantibodies are negative, and both parents have mild hyperglycemia. A heterozygous GCK pathogenic variant is identified. Which management strategy is supported by longitudinal natural history data?", "options": ["Metformin 500 mg twice daily", "Glipizide 5 mg daily", "Sitagliptin 100 mg daily", "No pharmacologic therapy", "Basal insulin 0.2 units/kg"], "answer": "D", "answer_index": 3, "explanation": "Glucokinase MODY resets the glucose threshold to ~140 mg/dL but maintains tight regulation around this setpoint; large cohort studies show no increased microvascular or macrovascular complications, making pharmacotherapy unnecessary. Sulfonylureas are ineffective as they don't correct the underlying glucokinase defect.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include young age, mild persistent hyperglycemia (fasting glucose 108-115 mg/dL, HbA1c 6.1-6.3%), normal BMI 22 kg/m², negative islet autoantibodies, family history of mild hyperglycemia, and confirmed heterozygous GCK pathogenic variant, consistent with MODY2 (glucokinase maturity-onset diabetes of the young). These findings imply a benign condition with reset glucose setpoint but no progression to complications, supporting no pharmacologic intervention. Main logical issue(s): none; the vignette provides sufficient discriminating details (e.g., genetic confirmation, negative autoantibodies ruling out type 1, normal BMI excluding type 2) to identify D as uniquely best, with alternatives inferior due to lack of necessity or efficacy in GCK defect. Main medical accuracy issue(s): none; aligns with current guidelines (e.g., ADA, ISPAD) that MODY2 requires monitoring but not routine therapy, as longitudinal data show no increased micro/macrovascular risks. Sulfonylureas are indeed ineffective, and other options like metformin, DPP-4 inhibitors, or insulin are unnecessary. Minimal fix: none needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include young age, mild persistent hyperglycemia (fasting glucose 108-115 mg/dL, HbA1c 6.1-6.3%), normal BMI 22 kg/m², negative islet autoantibodies, family history of mild hyperglycemia, and confirmed heterozygous GCK pathogenic variant, consistent with MODY2 (glucokinase maturity-onset diabetes of the young). These findings imply a benign condition with reset glucose setpoint but no progression to complications, supporting no pharmacologic intervention. Main logical issue(s): none; the vignette provides sufficient discriminating details (e.g., genetic confirmation, negative autoantibodies ruling out type 1, normal BMI excluding type 2) to identify D as uniquely best, with alternatives inferior due to lack of necessity or efficacy in GCK defect. Main medical accuracy issue(s): none; aligns with current guidelines (e.g., ADA, ISPAD) that MODY2 requires monitoring but not routine therapy, as longitudinal data show no increased micro/macrovascular risks. Sulfonylureas are indeed ineffective, and other options like metformin, DPP-4 inhibitors, or insulin are unnecessary. Minimal fix: none needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-006", "question": "A 65-year-old man with heart failure presents with LV wall thickness 15 mm, global longitudinal strain -8%, and apical sparing ratio 2.5. Serum lambda light chains are 180 mg/L with free light chain difference 150 mg/L. Which regimen has demonstrated survival benefit in stage IIIb AL amyloidosis with cardiac involvement?", "options": ["Bortezomib-cyclophosphamide-dexamethasone", "Daratumumab-bortezomib-dexamethasone", "Orthotopic heart transplant", "Doxycycline 100 mg twice daily", "Tafamidis 61 mg daily"], "answer": "B", "answer_index": 1, "explanation": "The ANDROMEDA trial demonstrated that daratumumab-based regimens achieve rapid and deep hematologic responses, translating to improved cardiac function and survival in high-risk AL amyloidosis. Tafamidis is indicated for transthyretin, not light-chain amyloidosis. Doxycycline remains investigational.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Heart failure with LV wall thickness 15 mm, impaired global longitudinal strain -8%, apical sparing ratio 2.5, elevated lambda light chains 180 mg/L, and free light chain difference 150 mg/L, collectively indicating stage IIIb AL cardiac amyloidosis. These findings point to light-chain amyloidosis, making daratumumab-bortezomib-dexamethasone the regimen with trial-proven survival benefit per ANDROMEDA study. Main logical issue(s), if any: None; stem provides sufficient discriminating details for a single best answer without contradictions or underspecification. Main medical accuracy issue(s), if any: None; aligns with current guidelines, as ANDROMEDA trial (2020) demonstrated superior hematologic response and survival with daratumumab addition to bortezomib-based therapy in high-risk AL amyloidosis, including cardiac involvement. Alternatives are appropriately inferior: A lacks daratumumab's benefit; C is not primary therapy; D is investigational; E is for ATTR amyloidosis. Minimal fix: No edit needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Heart failure with LV wall thickness 15 mm, impaired global longitudinal strain -8%, apical sparing ratio 2.5, elevated lambda light chains 180 mg/L, and free light chain difference 150 mg/L, collectively indicating stage IIIb AL cardiac amyloidosis. These findings point to light-chain amyloidosis, making daratumumab-bortezomib-dexamethasone the regimen with trial-proven survival benefit per ANDROMEDA study. Main logical issue(s), if any: None; stem provides sufficient discriminating details for a single best answer without contradictions or underspecification. Main medical accuracy issue(s), if any: None; aligns with current guidelines, as ANDROMEDA trial (2020) demonstrated superior hematologic response and survival with daratumumab addition to bortezomib-based therapy in high-risk AL amyloidosis, including cardiac involvement. Alternatives are appropriately inferior: A lacks daratumumab's benefit; C is not primary therapy; D is investigational; E is for ATTR amyloidosis. Minimal fix: No edit needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-007", "question": "A 4-day-old neonate exhibits burst-suppression pattern on EEG and multifocal seizures refractory to phenobarbital 40 mg/kg and levetiracetam 50 mg/kg. Targeted epilepsy panel reveals a de novo KCNQ2 gain-of-function mutation. Which anticonvulsant mechanism is most likely to achieve seizure freedom?", "options": ["GABAergic enhancement with clobazam", "Sodium channel blockade with phenytoin", "Sodium channel blockade with carbamazepine", "Synaptic vesicle modulation with brivaracetam", "Ketogenic diet 4:1 ratio"], "answer": "C", "answer_index": 2, "explanation": "Despite KCNQ2 encoding a potassium channel, gain-of-function mutations cause hyperexcitability that paradoxically responds best to sodium channel blockers like carbamazepine, which reduce overall neuronal firing. Phenobarbital and levetiracetam are often ineffective in this channelopathy.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Neonatal onset with burst-suppression EEG, multifocal seizures refractory to high-dose phenobarbital (GABAergic) and levetiracetam (SV2A modulator), and confirmed de novo KCNQ2 gain-of-function mutation, pointing to a channelopathy responsive to specific sodium channel blockade.\\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details (refractoriness to initial agents, genetic diagnosis) to identify carbamazepine-based sodium channel blockade as uniquely superior, with alternatives either mechanistically similar to failed therapies (A, D) or less targeted (B, E).\\nMain medical accuracy issue(s), if any: None; aligns with current guidelines for KCNQ2 encephalopathy, where gain-of-function mutations cause hyperexcitability paradoxically responsive to carbamazepine over other sodium blockers like phenytoin due to its use-dependent blockade and clinical evidence of efficacy; ketogenic diet is adjunctive but not primary.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Neonatal onset with burst-suppression EEG, multifocal seizures refractory to high-dose phenobarbital (GABAergic) and levetiracetam (SV2A modulator), and confirmed de novo KCNQ2 gain-of-function mutation, pointing to a channelopathy responsive to specific sodium channel blockade.\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details (refractoriness to initial agents, genetic diagnosis) to identify carbamazepine-based sodium channel blockade as uniquely superior, with alternatives either mechanistically similar to failed therapies (A, D) or less targeted (B, E).\nMain medical accuracy issue(s), if any: None; aligns with current guidelines for KCNQ2 encephalopathy, where gain-of-function mutations cause hyperexcitability paradoxically responsive to carbamazepine over other sodium blockers like phenytoin due to its use-dependent blockade and clinical evidence of efficacy; ketogenic diet is adjunctive but not primary.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-008", "question": "A 36-year-old woman with migraine with aura develops acute right hemiparesis (NIHSS 8) and arrives within 90 minutes of symptom onset. MRI shows anterior temporal lobe T2 hyperintensities and external capsule involvement. Which intervention is contraindicated due to disease-specific pathophysiology?", "options": ["IV tPA 0.9 mg/kg", "Aspirin 325 mg", "Clopidogrel 600 mg", "Supportive care in stroke unit", "Mechanical thrombectomy"], "answer": "A", "answer_index": 0, "explanation": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) involves fragile small vessels with thickened walls and perivascular deposits; thrombolysis carries excessive hemorrhagic risk due to vessel fragility. Mechanical thrombectomy is also contraindicated for lacunar strokes typical in CADASIL.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues: 36-year-old with migraine with aura, acute hemiparesis (NIHSS 8) within 90 minutes, MRI with anterior temporal T2 hyperintensities and external capsule involvement—classic for CADASIL, implying small vessel ischemic stroke. Main logical issue(s): Multiple options defensible as contraindicated due to CADASIL pathophysiology (NOTCH3-related vessel fragility and subcortical infarcts); A (tPA) due to high hemorrhagic risk from fragile vessels, E (thrombectomy) as disease causes lacunar strokes without LVO, making it inappropriate—author rationale explicitly states E is also contraindicated, creating tie. Stem is underspecified without vessel imaging (e.g., CTA) to confirm/absence of LVO, requiring assumption of typical CADASIL presentation for unique best. Main medical accuracy issue(s): tPA is high-risk and often avoided in CADASIL but not absolutely contraindicated per AHA guidelines (caution advised, not prohibition); thrombectomy not contraindicated by pathophysiology but irrelevant for small vessel disease—rationale overstates this. Minimal fix: Add 'CTA shows no large vessel occlusion' to stem to rule out LVO, making A uniquely contraindicated while clarifying E as not indicated rather than contraindicated.\",\n\"medical_accuracy_score\": 3,\n\"logical_validity\": false,\n\"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues: 36-year-old with migraine with aura, acute hemiparesis (NIHSS 8) within 90 minutes, MRI with anterior temporal T2 hyperintensities and external capsule involvement—classic for CADASIL, implying small vessel ischemic stroke. Main logical issue(s): Multiple options defensible as contraindicated due to CADASIL pathophysiology (NOTCH3-related vessel fragility and subcortical infarcts); A (tPA) due to high hemorrhagic risk from fragile vessels, E (thrombectomy) as disease causes lacunar strokes without LVO, making it inappropriate—author rationale explicitly states E is also contraindicated, creating tie. Stem is underspecified without vessel imaging (e.g., CTA) to confirm/absence of LVO, requiring assumption of typical CADASIL presentation for unique best. Main medical accuracy issue(s): tPA is high-risk and often avoided in CADASIL but not absolutely contraindicated per AHA guidelines (caution advised, not prohibition); thrombectomy not contraindicated by pathophysiology but irrelevant for small vessel disease—rationale overstates this. Minimal fix: Add 'CTA shows no large vessel occlusion' to stem to rule out LVO, making A uniquely contraindicated while clarifying E as not indicated rather than contraindicated.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-009", "question": "A 29-year-old man with lifelong recurrent fevers (>38.5°C), severe abdominal pain, myalgia, and periorbital edema has an identified TNFRSF1A cysteine mutation. Which biologic therapy is preferred over etanercept due to mechanistic considerations?", "options": ["Colchicine 0.6 mg twice daily", "Etanercept 50 mg weekly", "Anakinra 100 mg daily", "Canakinumab 150 mg every 8 weeks", "Tocilizumab 8 mg/kg monthly"], "answer": "C", "answer_index": 2, "explanation": "Tumor necrosis factor receptor-associated periodic syndrome involves misfolded TNFRSF1A that can bind etanercept, forming complexes that prolong inflammation. IL-1 receptor antagonism with anakinra bypasses this mechanism and is first-line therapy. Colchicine is ineffective for TRAPS.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues: Lifelong recurrent fevers >38.5°C, severe abdominal pain, myalgia, periorbital edema, and TNFRSF1A cysteine mutation diagnose TRAPS; question seeks biologic preferred over etanercept mechanistically. These drive toward IL-1 inhibitors avoiding TNF pathway issues, but fail to specify why anakinra over canakinumab. Main logical issue: Both C (anakinra, IL-1 receptor antagonist) and D (canakinumab, anti-IL-1β) are defensible as preferred over etanercept for targeting downstream IL-1 without interacting with mutant TNFRSF1A, leading to multiple equally reasonable best answers; underspecified details (e.g., disease severity, treatment duration, or approval status) prevent discrimination. Main medical accuracy issue: Keyed anakinra as first-line is reasonable but misses nuance—canakinumab is FDA-approved for TRAPS with RCT support, while anakinra is effective off-label; etanercept's described mechanism (forming pro-inflammatory complexes) is an oversimplification, as inefficacy stems more from failure to address intracellular signaling. Minimal fix: Add to stem 'short-acting IL-1 inhibitor for rapid control' to favor anakinra uniquely.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues: Lifelong recurrent fevers >38.5°C, severe abdominal pain, myalgia, periorbital edema, and TNFRSF1A cysteine mutation diagnose TRAPS; question seeks biologic preferred over etanercept mechanistically. These drive toward IL-1 inhibitors avoiding TNF pathway issues, but fail to specify why anakinra over canakinumab. Main logical issue: Both C (anakinra, IL-1 receptor antagonist) and D (canakinumab, anti-IL-1β) are defensible as preferred over etanercept for targeting downstream IL-1 without interacting with mutant TNFRSF1A, leading to multiple equally reasonable best answers; underspecified details (e.g., disease severity, treatment duration, or approval status) prevent discrimination. Main medical accuracy issue: Keyed anakinra as first-line is reasonable but misses nuance—canakinumab is FDA-approved for TRAPS with RCT support, while anakinra is effective off-label; etanercept's described mechanism (forming pro-inflammatory complexes) is an oversimplification, as inefficacy stems more from failure to address intracellular signaling. Minimal fix: Add to stem 'short-acting IL-1 inhibitor for rapid control' to favor anakinra uniquely.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-010", "question": "A 21-year-old woman with hypertension and a 4-cm adrenal mass has plasma normetanephrine 8.2 nmol/L (ref <0.6). Genetic testing reveals a pathogenic SDHB variant. Which preoperative preparation strategy addresses the unique catecholamine synthesis profile of SDH-related tumors?", "options": ["Phenoxybenzamine 10 mg twice daily for 14 days", "Metyrosine 250 mg four times daily for 7 days", "Phenoxybenzamine plus metyrosine for 10-14 days", "Immediate laparoscopic adrenalectomy", "Amlodipine 10 mg daily only"], "answer": "C", "answer_index": 2, "explanation": "SDH-related pheochromocytomas/paragangliomas exhibit high tyrosine hydroxylase activity and catecholamine synthesis rates, requiring both irreversible alpha-blockade (phenoxybenzamine) and catecholamine synthesis inhibition (metyrosine) for adequate preoperative preparation. Alpha-blockade alone may be insufficient for the catecholamine surge.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 21-year-old woman with hypertension, 4-cm adrenal mass, markedly elevated plasma normetanephrine (8.2 nmol/L, ref <0.6), and pathogenic SDHB variant, implying SDH-related pheochromocytoma/paraganglioma with high catecholamine synthesis. These clues support preoperative preparation addressing excessive catecholamine production and surge risk. The question focuses on the unique profile of SDH-related tumors, which often require enhanced management beyond standard alpha-blockade. Main logical issue(s): None; the vignette provides sufficient discriminating details (e.g., SDHB mutation, elevated normetanephrine) to identify C as uniquely best, with alternatives inferior (A: alpha-blockade alone insufficient for synthesis rates; B: synthesis inhibition without blockade; D: risky without prep; E: inappropriate monotherapy). Main medical accuracy issue(s): None major; aligns with guidelines (e.g., Endocrine Society) recommending alpha-blockade (phenoxybenzamine) as mainstay, with metyrosine added for high-output tumors like SDHB-related cases to inhibit tyrosine hydroxylase and mitigate intraoperative surges. This is clinically sensible and board-relevant, though metyrosine is adjunctive and not universally required. Minimal fix: None required; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 21-year-old woman with hypertension, 4-cm adrenal mass, markedly elevated plasma normetanephrine (8.2 nmol/L, ref <0.6), and pathogenic SDHB variant, implying SDH-related pheochromocytoma/paraganglioma with high catecholamine synthesis. These clues support preoperative preparation addressing excessive catecholamine production and surge risk. The question focuses on the unique profile of SDH-related tumors, which often require enhanced management beyond standard alpha-blockade. Main logical issue(s): None; the vignette provides sufficient discriminating details (e.g., SDHB mutation, elevated normetanephrine) to identify C as uniquely best, with alternatives inferior (A: alpha-blockade alone insufficient for synthesis rates; B: synthesis inhibition without blockade; D: risky without prep; E: inappropriate monotherapy). Main medical accuracy issue(s): None major; aligns with guidelines (e.g., Endocrine Society) recommending alpha-blockade (phenoxybenzamine) as mainstay, with metyrosine added for high-output tumors like SDHB-related cases to inhibit tyrosine hydroxylase and mitigate intraoperative surges. This is clinically sensible and board-relevant, though metyrosine is adjunctive and not universally required. Minimal fix: None required; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]